Vinorelbine versus paclitaxel for patients with advanced non-small cell lung cancer (NSCLC) and a performance status of 2
Φόρτωση...
Ημερομηνία
Συγγραφείς
Kosmidis, P. A.
Syrigos, K.
Kalofonos, H. P.
Dimopoulos, M. A.
Skarlos, D.
Pavlidis, N.
Boukovinas, I.
Bafaloukos, D.
Pectasides, D.
Bacoyiannis, C.
Τίτλος Εφημερίδας
Περιοδικό ISSN
Τίτλος τόμου
Εκδότης
Περίληψη
Τύπος
Είδος δημοσίευσης σε συνέδριο
Είδος περιοδικού
peer-reviewed
Είδος εκπαιδευτικού υλικού
Όνομα συνεδρίου
Όνομα περιοδικού
Anticancer Res
Όνομα βιβλίου
Σειρά βιβλίου
Έκδοση βιβλίου
Συμπληρωματικός/δευτερεύων τίτλος
Περιγραφή
AIM: The purpose of this study was to compare two single agents paclitaxel (intravenous) versus vinorelbine (oral) in non-small cell lung cancer (NSCLC) patients with performance status (PS):2. PATIENTS AND METHODS: The patients were randomized to receive either oral vinorelbine 60 mg/m(2) on days 1, 8, 15 every 4 weeks for 4 cycles (group A) or paclitaxel 90 mg/m(2) intravenously for 1 h on days 1, 8, 15 every 4 weeks for a total of 4 cycles (group B). RESULTS: Among the 74 eligible patients (36 in arm A and 38 in arm B) in arm A, two (6%) had a partial response (95% CI, 0.7-18.7) and 5 (14%) had stable disease (95% CI, 4.7-29.5). In arm B, five (13%) had a partial response (95% CI, 4.4-28.1) and 7 (18%) had stable disease (95% CI, 7.7-34.3). No significant difference was found in terms of clinical benefit between the two groups after two cycles of treatment except for appetite in favour of paclitaxel (p=0.01). Median survival was 3.1 months (95% CI, 2.2-4.0) for arm A and 5.1 months (95% CI, 2.7-7.6) for arm B (p=0.95). Toxicity was mild and only alopecia was more profound in the patients of arm B (p=0.008). CONCLUSION: No significant difference was found in clinical benefit between PS:2 NSCLC patients treated with either vinorelbine or paclitaxel.
Περιγραφή
Λέξεις-κλειδιά
Adenocarcinoma/drug therapy/mortality/secondary, Aged, Aged, 80 and over, Antineoplastic Combined Chemotherapy Protocols/*therapeutic use, Bone Neoplasms/drug therapy/mortality/secondary, Brain Neoplasms/drug therapy/mortality/secondary, Carcinoma, Large Cell/diagnosis/genetics, Carcinoma, Non-Small-Cell Lung/*drug therapy/*mortality/secondary, Carcinoma, Squamous Cell/drug therapy/mortality/secondary, Disease Progression, Female, Follow-Up Studies, Humans, Liver Neoplasms/drug therapy/mortality/secondary, Lung Neoplasms/drug therapy/mortality/pathology, Lymphatic Metastasis, Male, Middle Aged, Neoplasm Recurrence, Local/*drug therapy/mortality/pathology, Neoplasm Staging, Paclitaxel/administration & dosage, Small Cell Lung Carcinoma/drug therapy/mortality/secondary, Survival Rate, Treatment Outcome, Vinblastine/administration & dosage/analogs & derivatives
Θεματική κατηγορία
Παραπομπή
Σύνδεσμος
http://www.ncbi.nlm.nih.gov/pubmed/22213304
Γλώσσα
en
Εκδίδον τμήμα/τομέας
Όνομα επιβλέποντος
Εξεταστική επιτροπή
Γενική Περιγραφή / Σχόλια
Ίδρυμα και Σχολή/Τμήμα του υποβάλλοντος
Πανεπιστήμιο Ιωαννίνων. Σχολή Επιστημών Υγείας. Τμήμα Ιατρικής